GlassScriptPhysician profile
Seth M Egelston
NPI 1972550002
$1,522.60
in general payments reported to CMS, 2019-2025
23 companies · $167 in 2025
The $167 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.09 · 2020: $102 · 2021: $473 · 2022: $320 · 2023: $133 · 2024: $230 · 2025: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $529 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $529.35 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $205.73 | 2021-2025 | Vraylar |
| Biohaven Pharmaceuticals, INC. | $146.39 | 2021 | |
| Janssen Pharmaceuticals, INC | $141.69 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $138.37 | 2021-2023 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $135.10 | 2019-2022 | |
| Pfizer INC. | $123.16 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $102.99 | 2022 | |
| Lundbeck LLC | $92.54 | 2024-2025 | Rexulti |
| Novo Nordisk INC | $78.95 | 2021-2022 | |
| Lilly USA, LLC | $66.49 | 2021-2024 | Mounjaro, Zepbound |
| Amarin Pharma, INC. | $43.26 | 2020 | |
| Shionogi INC | $38.77 | 2024 | Fetroja |
| Astrazeneca Pharmaceuticals LP | $29.98 | 2024 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $29.69 | 2023 | Rexulti |
| Dexcom, INC. | $21.91 | 2024 | Dexcom G6 Transmitter |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $21.91 | 2025 | Capvaxive |
| Amgen INC. | $19.86 | 2025 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.35 | 2019 | |
| Astellas Pharma US INC | $18.08 | 2019 | |
| Avanir Pharmaceuticals, INC. | $17.50 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.90 | 2021 | |
| Orexo US, INC. | $14.19 | 2021 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Egelston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.